Products for Research Use Only

Azvudine

CAT: 0804-HY-19314-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19314-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Azvudine (RO-0622) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM) . Azvudine inhibits NRTI-resistant viral strains[1]. Azvudine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
CAS Number
1011529-10-4
Product Name Alternative
RO-0622; FNC
UNSPSC
12352005
Target
HBV; HCV; HIV; Reverse Transcriptase
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/azvudine.html
Purity
99.79
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)
Smiles
O[C@@H]1[C@](CO)(N=[N+]=[N-])O[C@@H](N2C(N=C(N)C=C2)=O)[C@H]1F
Molecular Formula
C9H11FN6O4
Molecular Weight
286.22
References & Citations
[1]Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9 (8) :e105617.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1; HIV-2
Citation 01
Acta Pharm Sin B. 2024 Mar 30.|Antiviral Res. 2025 Jan 16:235:106081.|NAR Mol Med. 2025 Aug 11.|Signal Transduct Target Ther. 2025 Jan 17;10 (1) :30.|Biomed Pharmacother. 2025 May 27:188:118215.